THE EFFECTS OF ROSUVASTATIN EFFECT ON THE KIDNEY IN MALE ALBINO RATS

Background and Aim: Rosuvastatin is known to competitively inhibit HMG-CoA reductase, selectively and reversibly, this enzyme converts HMG-CoA to mevalonic acid in the cholesterol biosynthesis pathway, which is the rate-limiting step in cholesterol synthesis. Rosuvastatin is one of the most important cholesterol-lowering stanins that has been on the market by AstraZeneca since 2003, with unique pharmacokinetic and pharmacodynamic properties. There are some studies that dealt with the effect of rosuvastatin on the kidneys and were contradictory in their results. Therefore, the aim of the current study was to evaluate the effect of rosuvastatin (pharma science Incorporated company - Montreal/ Canada) on the physiological and histopathological parameters in the kidneys of male albino rats. Material and Methods: Forty adult of albino rats were used in the study. After acclimation, the rats were randomly divided into four groups (8 rats in each group) as follows: The first control group: was given normal saline solution (NS), the second group 10 mg/kg rosuvastatin, the third group was given 20 mg/kg rosuvastatin, while the fourth group was given 40 mg/kg rosuvastatin. The dose was continued for 60 days in a once-daily dosing regimen. After the end of the experiment, chemical analyzes were performed for kidney function, including cystatin C and vitamin D3. Then the rats were dissected, and kidney tissues were taken for histological study